Five days after the coronavirus vaccination campaign began in Argentina with the Sputnik V vaccine, the first results have been known on the adverse effects that those who received the first dose had. A report published yesterday by the Ministry of Health indicates that of the 32,013 doses applied, they were notified 317 subsequent adverse events, only 1% had any symptoms that can be related to the vaccine produced by the Gateway Center of Russia.
These figures correspond to the first two days of the national campaign vaccination against Covid-19. These adverse events are those that have been reported until 11:59 p.m. local time on December 30, to the Integrated Health Information System of Argentina (SISA), according to the first vaccine safety surveillance report.
“44.2% of the Davis (adverse events) reported correspond to people with fever, headache and / or alias that started 6 to 8 hours after vaccination,” he explained.
These events are related to the Sputnik V vaccine, added the report, which details that among the expected reactions, they may occur: pain at the injection site, hypermedia, swelling. And that within the systemic reactions, they can present: short-lived flu-like syndrome with onset within 24 to 48 hours (characterized by chills, fever, arthralgia, magic, Athenian, malaise, headache) or less frequent gastrointestinal symptoms (nausea, dyspepsia, decreased appetite). ” These reactions last an average of 24 hours,” he explained.
Argentina began the simultaneous vaccination process throughout the country last Tuesday with the batch of 300,000 doses of the Russian Sputnik V vaccine received on Thursday of the previous week, which is applied to health personnel.
The report published today reported that 18 of the 24 jurisdictions in the country have reported adverse events to the SISA. “99.3% of the events reported were mild and moderate, which did not require hospitalization and progressed with full recovery,” he added.
With some distrust due to the lack of public dissemination of scientific information on the Russian vaccine, Sputnik V, Argentina applied the first dose, which must be completed after 21 days with the second component. The target population at this stage is the health personnel of large urban agglomerates, the health personnel of closed intensive care units, and the laboratory personnel, who manipulate the virus to carry out diagnoses.
Argentina has committed 51 million doses, according to the contracts that the country signed with AstraZeneca for 22.4 million doses, with the Russian Investment Fund for 20 million doses of the Sputnik V vaccine and through the Coax Mechanism of the World Health Organization for 9 million doses. In addition, the country continues to negotiate to purchase vaccines from Pfizer, SICOVAL and Sinopharm laboratories.
Today the only vaccine available is the first dose of the Russian vaccine. President, Alberto Fernandez, has said that Russia will deliver in the first days of January the second 300,000 doses, at the end of January 4 million of the first dose and 1 million of the second and in February the amount that remains to finish vaccinating 10 million people.
The intention is to continue in a next stage with the vaccination of adults older than 70 years; then adults between 60 and 69 years; the armed forces, security and prison services; teaching staff and then other strategic populations.
George is Digismak’s reported cum editor with 13 years of experience in Journalism